A more recent study showed that overexpression of PDE4D in the liver led to the development of NAFLD and hypertension in mice, which was attenuated by PDE4 inhibitor treatment [60]. This evidence concerns the gene PDE4D and metabolic dysfunction-associated steatotic liver disease.